A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

por Hajek, Roman, Pour, Ludek, Ozcan, Muhit, Martin Sánchez, Jesus, García Sanz, Ramon, Anagnostopoulos, Achilles, Oriol, Albert, Cascavilla, Nicola, Terjung, Andreas, Lee, Yihua, Briso, Eva M., Dobkowska, Edyta, Hauns, Bernhard, Špička, Ivan
Publicado 2020